Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about UPB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Verekitug | Severe Asthma | Phase 2 · NCT06966479 | Active not recruiting |
| UPB-101 | Asthma | Phase 1 · NCT05448651 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
UPB holds $207.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $44.9M/quarter from operations, an estimated runway of 13.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 38 · Moderate
Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements through 2027.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when UPB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Erez Chimovits Director · +34,192 options |
Insider | 4,554,873 | 8.31% | 2024-10-15 |
| Norges Bank | Institution (13G, 5%+) | 4,206,586 | 7.67% | 2026-06-30 |
| FMR LLC | Institution (13G, 5%+) | 3,793,955 | 6.92% | 2026-10-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,814,714 | 5.14% | 2026-06-30 |
| Everett Rand Sutherland Chief Executive Officer, Director · +725,000 options |
Insider | 68,717 | 0.13% | 2026-09-16 |
| Aaron Deykin Chief Medical Officer · +261,000 options |
Insider | 32,302 | 0.06% | 2026-09-16 |
| Michael Gray CFO and COO · +286,500 options |
Insider | 27,942 | 0.05% | 2026-09-16 |
| Adam Houghton Chief Business Officer · +215,000 options |
Insider | 22,901 | 0.04% | 2026-09-16 |
| Allison Ambrose General Counsel · +176,000 options |
Insider | 15,563 | 0.03% | 2026-09-16 |
Share count 54,811,391 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UPB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →